Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year 1 with 60% of patients experiencing relapse or death within 12 months 2 Management releases Virtual Investor “What This Means” segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML.
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib
Generated revenue of $5,713,158 in Q1 2025 Achieved 30% EBITDA improvement over Q1 2024 Continuation of optimization efforts post Volatus and Drone Delivery Canada merger of equals Subsequent to quarter end, closed $3,000,000 fully subscribed LIFE Offering Subsequent to quarter end, announced closing of shares for debt transaction of $2,646,000 and an additional $446,400, strengthening balance sheet Volatus will host a webinar and live Q&A on Monday, June 2, 2025, at 8 am ET (see registration link below). TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the three months ended March 31, 2025 (Q1 2025).
5 Feb 2025 Date | | - Cons. EPS | - EPS |
6 Nov 2024 Date | | - Cons. EPS | - EPS |
6 Aug 2024 Date | | - Cons. EPS | - EPS |
1 May 2024 Date | | 4.1 Cons. EPS | - EPS |
7 Feb 2024 Date | | 4.48 Cons. EPS | 4.44 EPS |
5 Feb 2025 Date | | - Cons. EPS | - EPS |
6 Nov 2024 Date | | - Cons. EPS | - EPS |
6 Aug 2024 Date | | - Cons. EPS | - EPS |
1 May 2024 Date | | 4.1 Cons. EPS | - EPS |
7 Feb 2024 Date | | 4.48 Cons. EPS | 4.44 EPS |
Software - Infrastructure Industry | Technology Sector | Mr. Ronald F. Clarke CEO | XSTU Exchange | US3390411052 ISIN |
US Country | 10,500 Employees | - Last Dividend | - Last Split | 15 Dec 2010 IPO Date |
FLEETCOR Technologies, Inc. is a prominent payments company that facilitates a wide range of expense management solutions for businesses and consumers, particularly those related to vehicle, lodging, and corporate payments. Having a global footprint, the company operates not only in the United States but also has a significant presence in Brazil, the United Kingdom, and other international markets. The company's operations are segmented into Vehicle Payments, Corporate Payments, Lodging Payments, and Others, demonstrating a diversified portfolio of payment solutions. Founded in 1986 and headquartered in Atlanta, Georgia, FLEETCOR has grown to become a key player in the payment solutions sector, serving a wide array of customers including businesses, merchants, consumers, and payment networks.
FLEETCOR Technologies, Inc. offers a comprehensive array of products and services tailored to meet the specific needs of their clients, ranging from vehicle payment solutions to corporate payment systems and beyond: